Cidara Therapeutics, Inc. (NASDAQ:CDTX) Director Timothy R. Franson Acquires 7,000 Shares of Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Director Timothy R. Franson bought 7,000 shares of the business’s stock in a transaction on Monday, September 13th. The stock was purchased at an average price of $2.12 per share, for a total transaction of $14,840.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

NASDAQ:CDTX opened at $2.02 on Wednesday. Cidara Therapeutics, Inc. has a twelve month low of $1.46 and a twelve month high of $3.40. The firm has a market capitalization of $100.00 million, a price-to-earnings ratio of -1.82 and a beta of 1.36. The stock’s 50 day moving average price is $1.83 and its two-hundred day moving average price is $2.07.

Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Thursday, August 12th. The biotechnology company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.40. Cidara Therapeutics had a negative net margin of 117.68% and a negative return on equity of 336.43%. As a group, equities research analysts forecast that Cidara Therapeutics, Inc. will post -1.03 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. BVF Inc. IL grew its holdings in Cidara Therapeutics by 16.2% during the second quarter. BVF Inc. IL now owns 4,346,904 shares of the biotechnology company’s stock worth $8,781,000 after purchasing an additional 607,200 shares during the period. Millennium Management LLC lifted its position in shares of Cidara Therapeutics by 810.8% in the second quarter. Millennium Management LLC now owns 580,793 shares of the biotechnology company’s stock valued at $1,173,000 after buying an additional 517,023 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Cidara Therapeutics by 29.4% in the second quarter. Renaissance Technologies LLC now owns 1,046,303 shares of the biotechnology company’s stock valued at $2,114,000 after buying an additional 237,800 shares during the last quarter. Tibra Equities Europe Ltd acquired a new stake in shares of Cidara Therapeutics in the second quarter valued at approximately $353,000. Finally, Ergoteles LLC acquired a new stake in shares of Cidara Therapeutics in the second quarter valued at approximately $329,000. 41.34% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research upgraded Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 4th.

About Cidara Therapeutics

Cidara Therapeutics, Inc is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Further Reading: Bollinger Bands

Insider Buying and Selling by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.